<http://schema.org/description>
"Higher research and development costs coupled with an absence of milestone and license fee revenue sends ImmunoGen&amp;#39;s loss markedly higher. "^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.fool.com/investing/general/2014/04/25/rising-rd-expenses-drive-immunogens-q3-loss-signif.aspx>